FN Media Group Presents Oilprice.com Market Commentary
London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy. Both these have been undergoing continual digital disruption …But there’s more to come. Mentioned in today’s commentary includes: Brookfield Renewable Partners LP (NYSE:BEP), Lifestance Health Group Inc (NASDAQ:LFST), Teladoc Health Inc (NYSE:TDOC), Mind Medicine (MindMed) Inc (NASDAQ:MNMD), Intra-Cellular Therapies Inc (NASDAQ:ITCI).
In healthcare and wellness, global VC funding for digital health companies hit $15 billion in the first half of this year… and $19 billion if you include public market financing and debt. And now, we’re looking at artificial intelligence that empowers consumers to take control of their healthcare with a stunning new app that is trained by doctors to think like a doctor.
In energy, there are few segments as exciting as hydrogen. There is projected to be $500 billion in new investment in hydrogen through 2030. Over 130 large-scale hydrogen projects have been announced just since February this year, adding up to a total of nearly 360 projects.
Hydrogen has a major advantage over other energy sources because it burns hot and clean and has the potential to cut 20% of global industrial carbon emissions, and could even replace coal, according to Bloomberg.
This will hit the big time as soon as it can be produced for $1 a kilogram – it’s competitive price point. That’s why all the big money is rushing into this. BNEF estimates it will reach that price level by 2030.
The Hydrogen Boom
Brookfield Renewable Partners LP (NYSE:BEP) is a great way to get in on hydrogen without risking everything on a clean energy savior that could be commercially competitive by 2030.
Brookfield is a global giant when it comes to renewables, and hydrogen is its newest game. This time last year, Brookfield joined forces with one of the most exciting pure-play hydrogen fuel cell stocks, Plug Power (PLUG). PLUG has had its ups and down, and might now be entering another new phase of reward for investors, but it’s Brookfield that is the steady climber in the sector.
Hydrogen only adds to an already huge portfolio of thousands of power-generating assets. And when it cracks hydrogen, too, especially the green variety, there will be no stopping it.
BEP is trading lower this year, despite the fact that it is one of the biggest players on the renewable energy scene–and one of the smartest. That makes it a good time to buy, while soaring oil and gas prices are distracting everyone from future realities.
When the commercial hydrogen code is finally cracked–and again, Bloomberg thinks that will be by 2030–BEP will be one to come out on top. But even without hydrogen, keep this in mind: Brookfield’s global collection of hydroelectric power plants accounts for half of its revenue. And that’s preferable to solar and wind right now because hydropower isn’t intermittent. Furthermore, that nice revenue base is catapulting Brookfield into other areas of clean energy.
Telehealth Is Just Getting Started
The second story on our big industry disruption list is Treatment.com International Inc. (TRUE; TREIF), one of the most interesting fixes for a very broken American healthcare system. And the timing is perfect on this one: Treatment.com is about to launch its groundbreaking AI app: Cara, powered by its unique Global Library of Medicine (GLM).
Cara is the most sophisticated AI targeting the symptom checking market because it has been trained by a global team of doctors to think like a doctor and provide consumers with a way to truly diagnose their symptoms without relying on the fear mongering of “Dr. Google”, the cookie-cutter search engine of WebMD or the dangerous medical advice floating around TikTok.
Cara makes personalized health assessments and wellness management based on data from actual doctors as easy as clicking a few buttons … without stepping into a doctor’s office, or paying for a doctor’s visit. It’s absolutely free.
How does it work? The AI behind it might be highly sophisticated and complex, but from a user’s perspective, nothing could be simpler: Cara asks you questions about your symptoms and then sorts through millions of pieces of information. It covers your historical medical cases, demographic data and continual advances in medical knowledge.
It can all be integrated with Apple Health Kit, Apple Watch, and FitBit .. but the biggest note of confidence in the new AI that seems ready to disrupt healthcare as we know it is this: The hundreds of doctors who trained it made it so good that it’s been licensed to test medical students at the University of Minnesota’s Medical School.
The app industry is one of the cleanest out there when it comes to costs and revenues …For apps, the big costs are all taken care of upfront, with development. After that, it’s all about revenues, not costs.
While the initial basic Cara app is free, premium app subscriptions will be just one revenue stream. Specialized medical segments come with a subscription, and Cara has a line-up planned after the launch. But Cara AI connects everything: wellness, telemedicine, pharma, and health products. That means there’s value in health and wellness products, too, as well as in connecting users to the best telemedicine offerings.
What investors should be latching onto most, though, is the massive amounts of data Cara will be collecting from users. That health data, along with Cara’s artificial intelligence IP, make it potentially worth multiple times more than just another app.
Everyone will want this data … governments, healthcare providers, insurance companies, pharmacies … and quite possibly, those soaring telemedicine businesses that have become the kings of our post-COVID environment. In just three years from now, market predictions see healthcare big data hitting $68 billion.
That’s a huge number to tap into for a small Canadian company that just listed publicly in April. WebMD, the most popular “symptom checker” out there, is worth $2.8 billion, without any artificial intelligence … without any personalized healthcare assessments … and without any attempt to think like a doctor.
Demand for AI that can help us manage our health and check our symptoms without going to the doctor first, is voracious. Treatment.com (TRUE; TREIF) is the answer to that demand, and the first to offer AI trained by doctors. After Cara launches later this year, this $170M market cap company could become valued at multiples higher.
The Healthcare Industry Is Evolving
Lifestance Health Group Inc (NASDAQ:LFST) is a company that looks beyond profitability, as well. It is a company that truly cares about the well-being of the world. Recently, Lifestance Health Group donated a significant chunk of change to the U.S. Paralympic Foundation and another donation to the Mental Health Coalition. “Unifying physical and mental health is critically important for all of us, and we stand in support of elite athletes like Simone Biles and Naomi Osaka encouraging the destigmatization of mental health and speaking openly about their own challenges,” said Mike Lester, Director, LifeStance Health Foundation, said in a release.
On October 6th, Teladoc Health Inc (NYSE:TDOC) announced that its primary care service, Primary360, will be available to commercial health plans, employers, and other organizations that sponsor health care for individuals and families in the United States. This is huge because it will open the door to a massive amount of people who may have otherwise fallen between the cracks.
Donna Boyer, chief product officer at Teladoc Health, explained, Primary360 has the unique power to drive the unified health care experience that consumers are demanding by removing longstanding barriers like access, cost and convenience,” adding “Primary360 gives people greater control over their healthcare experience without losing the personal connection they seek – all from a brand that they trust.”
Mind Medicine (MindMed) Inc (NASDAQ:MNMD) is an innovative, tech-driven company that provides mental health care services to patients through its online platform. Our team of experts are passionate about the power of technology and how it can be used to create a more accessible healthcare system. MindMedicine’s mission is to provide affordable, convenient, and high-quality mental health care for people around the world who need support but don’t have access.
Recently, Mind Medicine announced a major partnership with Sphere Health to launch a new study harnessing existing consumer technology to build an exciting new data set which could be used to create more efficient machine learning tools to potentially show association with and predict symptoms of mental health issues such as anxiety and depression.
Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a pharmaceutical company based in the US that specializes in developing treatments for chronic illnesses, such as cancer and diabetes. They are currently focused on researching new therapeutic proteins to treat type 2 diabetes, which has been identified by the World Health Organization (WHO) as one of the most pressing health concerns of our time. Intra-Cellular Therapies Inc., with its focus on research, development and commercialization of biopharmaceuticals, offers hope to people who suffer from these conditions.
Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, also highlighted that new medications progressing in trials helped boost investor confidence, noting, “We are pleased with our strong results in the second quarter. Our sNDAs for bipolar depression are under review by the FDA and our CAPLYTA strategy continues to make substantial progress with our commercialization in schizophrenia, along with our preparations for a potential label expansion into bipolar depression. We have initiated patient enrollment in our Phase 3 program in MDD and continue our programs studying other depressive disorders.”
By Charles Kennedy
** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY! **
This article is a paid advertisement. Advanced Media Solutions Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International, Inc. Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher to produce and disseminate six articles profiling the Company at a rate of seventy-five thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the company’s products, the anticipated growth of the market for AI-assisted products generally, the anticipated growth of the market for app-based products generally, the anticipated launch date for the company’s products, the anticipated growth of the market for health care app-based products generally, the anticipated launch date for the company’s products, and the anticipated growth and expansion of the medical library to which the company’s products have access. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the AI technology used in the company’s products, the company’s ability to effectively market the company’s products to customers within its three anticipated revenue streams, supply chain constraints, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. oilprice.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
DISCLAIMER: OilPrice.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with OilPrice.com or any company mentioned herein. The commentary, views and opinions expressed in this release by OilPrice.com are solely those of OilPrice.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: firstname.lastname@example.org U.S. Phone: +1(954)345-0611